The Paper | Multiple Studies from SSE STAR Market Innovative Drug Enterprises to Be Presented at 2026 ASCO Annual Meeting

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 29 to June 2. As one of the most influential academic events in the field of global oncology, this year's meeting brings together top scholars and cutting-edge research from around the world. Chinese scholars will present 95 studies selected for key sessions including oral presentations, rapid oral presentations, clinical science symposia, and education sessions—setting a new record compared to 48 in 2024 and 72 in 2025. Among these, 12 studies have been selected for Late-Breaking Abstracts (LBAs).

It is reported that at this annual global oncology gathering, several SSE STAR Market-listed innovative drug enterprises, including ‌BeOne Medicines (688235), Biokin (688506), and Dizal Pharmaceutical (688192), will unveil key clinical data. Among them, two studies have been selected for the LBA session, and more than ten studies will be presented as oral reports, covering major cancer types such as lung cancer, breast cancer, digestive system tumors, urological tumors, and hematologic malignancies. These developments highlight the growing global academic influence of China's innovative drug industry. (Reported by Tian Zhongfang, The Paper)